Transparency Initiative to provide more information on FDA regulation and drug development

被引：0
|
作者：
Wechsler, Jill
机构：
来源：
FORMULARY | 2010年 / 45卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：232 / 233
页数：2
相关论文
共 50 条
  • [21] The development of the Extractive Industries Transparency Initiative
    Short, The Rt Hon Clare
    JOURNAL OF WORLD ENERGY LAW & BUSINESS, 2014, 7 (01): : 8 - 15
  • [22] FDA expands drug labeling, permits more information in DTC broadcast advertising
    Wechsler, J
    FORMULARY, 1997, 32 (10) : 1094 - &
  • [23] ACCELERATING DRUG DISCOVERY AND DEVELOPMENT BY CREATING A MORE EFFECTIVE, EFFICIENT FDA
    DESANTE, KA
    SCIENTIST, 1995, 9 (24): : 12 - 12
  • [24] DENATURALIZING TRANSPARENCY IN DRUG REGULATION
    Herder, Matthew
    MCGILL JOURNAL OF LAW AND HEALTH, 2015, 8 (02): : S57 - S143
  • [25] Regulation FDA seeks more flexibility
    Adriaanse, Chris
    CHEMISTRY & INDUSTRY, 2010, (20) : 9 - 9
  • [26] ''No more drug lag'', insists FDA
    Wechsler, J
    FORMULARY, 1996, 31 (03) : 236 - &
  • [27] Clinical Trial Transparency: The FDA Should and Can Do More
    Kapczynski, Amy
    Kim, Jeanie
    JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 33 - 38
  • [28] FDA faces congressional probes and more transparency and organizational changes
    Wechsler, Jill
    FORMULARY, 2011, 46 (02) : 66 - 67
  • [29] Neonatal Safety Information Reported to the FDA During Drug Development Studies
    Debbie Avant
    Gerri Baer
    Jason Moore
    Panli Zheng
    Alfred Sorbello
    Ron Ariagno
    Lynne Yao
    Gilbert J. Burckart
    Jian Wang
    Therapeutic Innovation & Regulatory Science, 2018, 52 : 100 - 108
  • [30] Neonatal Safety Information Reported to the FDA During Drug Development Studies
    Avant, Debbie
    Baer, Gerri
    Moore, Jason
    Zheng, Panli
    Sorbello, Alfred
    Ariagno, Ron
    Yao, Lynne
    Burckart, Gilbert J.
    Wang, Jian
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (01) : 100 - 108
12345